IPCA Laboratories share news and announcements
NSE: IPCALABBSE: 524494Pharmaceuticals & BiotechnologyMid Cap
Last close ₹1,953.30up ₹49.80 (2.62%)BSE ₹1,951.25
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,903.50.
52-week range of traded prices to 23 Oct 2026
₹1,251.60Low, 24 Oct 2025₹2,038.00High, 18 Sep 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹49,556 Cr229th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 13 Aug 2026
- 37.8
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 6.1
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.31%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 13 Aug 2026
- 17.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 13 Aug 2026
- 17.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.07
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 3,18,78151.9% delivered
IPCA Laboratories board meetings
123 filed, newest first. Page 2 of 3.
Aug 2020
Jul 2020
Jun 2020
Jan 2020
Nov 2019
7 Nov · Board meeting
Oct 2019
Sep 2019
26 Sep · Board meeting
Jul 2019
May 2019
Feb 2019
12 Feb · Board meeting
Jan 2019
Oct 2018
Jul 2018
May 2018
Jan 2018
Nov 2017
14 Nov · Board meeting
Jul 2017
May 2017
Apr 2017
Jan 2017
Oct 2016
Aug 2016
May 2016
Jan 2016
Oct 2015
Jul 2015
May 2015
Feb 2015
Jan 2015
Oct 2014
29 Oct · Board meeting
Inter-alia, to take on record the Unaudited Financial Results for the quarter and half year ended September 30, 2014.
Jul 2014
May 2014
Jan 2014
Oct 2013
7 Oct · Board meeting
Inter-alia, to consider following: (1) Unaudited Financial Results for the quarter and half year ended September 30, 2013; and (2) Interim Dividend for the financial year 2013-14.
Jul 2013
3 Jul · Board meeting
Inter-alia, to take on record the Unaudited Financial Results for the 1st Quarter ended June 30, 2013.
May 2013
6 May · Board meeting
Inter alia, to consider : (1) the Audited Financial Results for the financial year ended March 31, 2013; and (2) recommendation of final dividend for the financial year ended March 31, 2013.
Jan 2013
16 Jan · Board meeting
Inter-alia, to consider the following : (1) Unaudited Financial Results for 3rd Quarter and nine months ended December 31, 2012; and (2) Allotment of 48,750 equity shares of Rs.2/- each on exercises of options under Ipca Laboratories Ltd- Employees Stock Option Scheme-2006(ESOS).
Oct 2012
9 Oct · Board meeting
Inter-alia, to consider following: (1) Unaudited Financial Results for the quarter and half year ended September 30, 2012; and (2) Interim Dividend for the financial year 2012-13.
Jul 2012
16 Jul · Board meeting
Inter-alia, to take on record the Unaudited Financial Results for the 1st Quarter ended June 30, 2012.
May 2012
17 May · Board meeting
Inter-alia, to consider : (1) The Audited Financial Results for the financial year ended March 31, 2012; and (2) Recommendation of final dividend for the financial year ended March 31, 2012.9 May · Board meeting
Inter-alia, to consider and to take on record : (a) The order passed by the Hon'able High Court of Judicature at Bombay and Hon'able High Court of Gujarat approving the Scheme of Amalgamation of M/s. Tonira Pharma Ltd. with the Company; and (b) To fix the Record Date for the purpose of M/s. Tonira Parma Limited members entitlement of the Company shares in the ratio of 6 (Six) fully paid up equity shares of Rs. 2/- each of the Company for every 100 (One Hundred) fully paid up equity shares of Rs. 10/- each in Tonira Pharma Limited pursuant to the said Company's merger with the Company.
Jan 2012
17 Jan · Board meeting
Inter-alia, to consider the following : (1) Unaudited Financial Results for 3rd Quarter and nine months ended December 31, 2011; and (2) 2nd Interim Dividend for the financial year 2011-12.16 Jan · Board meeting
Inter-alia to consider Allotment of equity shares on exercise of optiions under Ipca Laborartories Ltd- Employees Stock Option Scheme - 2006 (ESOS).
Oct 2011
17 Oct · Board meeting
Inter-alia, to consider following: (1) Unaudited Financial Results for the quarter and half year ended September 30, 2011; and (2) Interim Dividend for the financial year 2011-12.
Sep 2011
19 Sep · Board meeting
Board of Directors of the Company at its meeting held on September 17, 2011, inter alia, have approved amalgamation of Tonira Pharma Limited with the Company with effect from April 01, 2011 (being the appointed date) through a Scheme of Amalgamation. The Scheme envisages an exchange ratio of 6 (Six) equity shares of Rs. 2/- each fully paid-up of Ipca Laboratories Limited for every 100 (One Hundred) equity shares of Rs. 10/- each fully paid-up of Tonira Pharma Limited. The exchange ratio is based on the joint valuation made by M/s. Natvarlal Vepari & Co., Chartered Accountants and M/s. G. M. Kapadia & Co., Chartered Accountants. The proposed scheme of Amalgamation will be subject to all necessary permissions and approvals, as may be required.9 Sep · Board meeting
Inter-alia, to consider the Amalgamation / Merger of Tonira Pharma Limited with the Company.